AMPD1 Antibody

Adenosine monophosphate deaminase 1 catalyzes the deamination of AMP to IMP in skeletal muscle and plays an important role in the purine nucleotide cycle. Two other genes have been identified, AMPD2 and AMPD3, for the liver- and erythocyte-specific isoforms, respectively. Deficiency of the muscle-specific enzyme is apparently a common cause of exercise-induced myopathy and probably the most common cause of metabolic myopathy in the human.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Mouse.

We have publications tested in 2 applications: WB, Western Blot.

Showing Publications 1 - 3 of 3.

Publications using NBP2-24509	Applications	Species
Yamada T, Ashida Y, Tamai K et al. Improved skeletal muscle fatigue resistance in experimental autoimmune myositis mice following high-intensity interval training Arthritis research & therapy 2022-06-27 [PMID: 35761371] (WB, Mouse)	WB	Mouse
Lopez R, Marzban B, Gao X et al. Impaired Myocardial Energetics Causes Mechanical Dysfunction in Decompensated Failing Hearts Function (Oxf) 2020-09-22 [PMID: 33074265] (Western Blot)	Western Blot
Coley W, Rayavarapu S, Pandey GS et al. The molecular basis of skeletal muscle weakness in a mouse model of inflammatory myopathy. Arthritis Rheum. 2012-11-01 [PMID: 22806328]

Array NBP2-24509

• AMPD1 Antibodies
• AMPD1 Lysate
• AMPD1 Proteins